As a result, ANGPTL3 has attracted much attention globally as a new therapeutic target for dyslipidemia, and in 2021, the U.S. Food and Drug Administration approved a monoclonal inhibitory antibody against ANGPTL3 (Evinacumab) as a drug for add-on treatment of adult and pediatric patients ages 12 and above with homozygous familial hypercholesterolemia (HoFH)4. The gene discussed is ANGPTL3; the disease is familial hypercholesterolemia.